Arcellx shares jump on strong multiple myeloma trial results
I'm PortAI, I can summarize articles.
Arcellx Inc. (NASDAQ:ACLX) rallied 13.6% in premarket trading Monday after releasing encouraging data from its pivotal Phase 2 iMMagine-1 trial evaluating anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. In the latest update, the company reported a 96% overall response rate and a 74% complete response/stringent complete response rate at a median […]
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments